BGLAF (BioGaia AB) Quality Rank


BGLAF BioGaia AB BGLAF
100 GF Score
Price $12.20
GF Value $13.05
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BioGaia AB Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

BioGaia AB Quality Rank Related Terms

BGLAF
100GF Score
BioGaia AB BGLAF
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioGaia AB (BGLAF) Overvalued in 2026?

Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued. The current stock price of $12.20 is trading 6.5% below its estimated GF Value™ of $13.05. GuruFocus considers BioGaia AB to be Fairly Valued.

Key valuation signals for BGLAF:

  • Quality Rank:
  • GF Value™: $13.05 vs. price of $12.20 (6.5% below fair value)
  • GF Score™: 100/100 with 5 warning signs

No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioGaia AB Business Description

Address Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score

Get the complete analysis for BGLAF

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.20
Price
$13.05
GF Value